文章：

打破癌症发展势头：CDK4/6抑制剂与联合疗法的前景

Breaking Cancer’s Momentum: CDK4/6 Inhibitors and the Promise of Combination Therapy

原文发布日期：11 June 2025

DOI: 10.3390/cancers17121941

类型: Article

开放获取: 是

英文摘要：

CDK4/6 inhibition represents a new generation of cancer therapies, targeting CDK4/6 complexes to induce cell cycle arrest in the G1 phase. These inhibitors have been widely used in combination with hormone receptor antagonists for treating ER+/HER2− breast cancer, achieving significant clinical success. Building on this progress, ongoing research explores novel combination therapies and expands the application of CDK4/6 inhibitors to other diseases. However, challenges remain, including variable cellular responses and the rapid development of drug resistance. Recent studies have uncovered new resistance mechanisms and their unexpected effects on cell metabolism, autophagy, and the tumor microenvironment beyond cell cycle arrest. This review provides a comprehensive overview of the mechanisms by which CDK4/6 inhibitors combat cancer and explores their potential for more effective and personalized treatment strategies.

摘要翻译： 

CDK4/6抑制代表新一代癌症疗法，通过靶向CDK4/6复合物诱导细胞周期停滞于G1期。这类抑制剂已广泛联合激素受体拮抗剂用于治疗ER+/HER2−乳腺癌，取得显著临床成效。基于此进展，当前研究正探索新型联合治疗方案，并将CDK4/6抑制剂的应用拓展至其他疾病领域。然而仍存在诸多挑战，包括细胞应答差异及耐药性的快速产生。最新研究揭示了超越细胞周期阻滞的新型耐药机制，及其对细胞代谢、自噬和肿瘤微环境的意外影响。本综述系统阐述CDK4/6抑制剂的抗癌作用机制，并探讨其在开发更有效个体化治疗策略中的潜力。

原文链接：

Breaking Cancer’s Momentum: CDK4/6 Inhibitors and the Promise of Combination Therapy